Requests for Applications
Stem Cell Funding Opportunities
All of CIRM's stem cell research funds are given out through direct requests for applications (RFAs). When concepts for new RFAs are approved by the governing board, they are listed below as upcoming RFAs. Once those RFAs are posted and are open for applications, they are listed as Current Requests for Applications. Applications are reviewed by 15 members of the Scientific and Medical Research Funding Working Group (Grants Working Group), who score the grants and provide funding recommendations to the board. Those review reports are posted on this page prior to the meeting in which our governing board votes on which applications to fund.
Related information about CIRM stem cell grants
- Search all funded grants
- See charts showing our grant distribution
- See a list of CIRM grantee institutions
- Read information about managing CIRM grants
- See how much money CIRM has committed and spent on stem cell grants
- Receive email announcements when new RFAs are posted
|Collaborative Funder||RFA posting|
|Disease Team Therapy Development IV||March 2014|
|Basic Biology VI||May 2014|
Current Requests for Applications
RFA 13-07: CIRM Alpha Stem Cell Clinics Network: Coordinating and Information Management Center
The purpose of RFA 13-07 is to fund a Coordinating and Information Management Center (CIMC) for the CIRM Alpha Stem Cell Clinics (CASC) Network. The aim of the network is to accelerate therapeutic development of stem cell therapies by providing a high quality, efficient infrastructure to support clinical testing of investigational products, and delivery of approved therapies. The Network will be composed of up to five Alpha Stem Cell Clinics Sites (funded by RFA 13-06) and one Coordinating and Information Management Center (CIMC). The CIMC will support the network by providing consulting services for clinical trial design and operations, provision of public and patient educational services, a resource for data and information management, and healthcare economics expertise to inform clinical trial and reimbursement strategies.
RFA 13-06: CIRM Alpha Stem Cell Clinics Network: Alpha Stem Cell Clinics
The purpose of RFA 13-06 is to fund up to five Alpha Stem Cell Clinics as part of the CIRM Alpha Stem Cell Clinics (CASC) Network. The goal of the CASC Network is to accelerate therapeutic development of stem cell therapies by providing a high quality, efficient infrastructure to support clinical testing of investigational products, and delivery of approved therapies. The Network will be composed Alpha Stem Cell Clinics Sites and a Coordinating and Information Management Center (funded by RFA 13-07). The Alpha Stem Cell Clinics will provide critical operational support for the conduct of clinical trials for investigational stem cell therapies and will operate as a center of excellence for approved stem cell therapies.
RFA 13-05: CIRM Tools and Technologies III Awards
The CIRM Tools and Technologies initiative intends to support research that can address regenerative medicine’s unique translational challenges. Tools and Technologies III will support the creation, design and testing of broadly applicable novel tools and technologies and the optimization, improvement, standardization or scale-up of existing tools or technologies for addressing translational bottlenecks to stem cell therapies.
RFA 13-04: External Innovation Pilot Program
The purpose of this RFA is to bring into California the most promising transformative research going on outside the state. CIRM is releasing this RFA as a pilot program. This program would provide funding for key personnel in California to join innovative external studies in order to accelerate those studies towards clinical applications.
RFA 13-03A/B: CIRM Strategic Partnership III Awards
The purpose of the Strategic Partnership Awards Initiative (“Initiative”) is to attract industry engagement and investment in CIRM funded stem cell research. The intent of the Initiative is to create incentives and processes that will: (i) enhance the likelihood that CIRM funded projects will obtain funding for future clinical trials (e.g. follow-on financing), (ii) provide a source of co-funding for the earlier stages of clinical development, and (iii) enable CIRM funded projects to access expertise within pharmaceutical and large biotechnology partners in areas such as discovery, preclinical, regulatory, clinical trial design and manufacturing process development.
CIRM conducted a webinar for prospective applicants on August 7, 2013 to address questions about these RFAs and the application process. To view the recording or access a summary of the Q and A, go to http://www.cirm.ca.gov/our-funding/webinar-cirm-strategic-partnership-iii-awards.
RFA 13-02: CIRM Basic Biology Awards V
The CIRM Basic Biology Awards V will fund research tackling significant, unresolved issues in human stem cell biology. These awards will comprise two categories, or “tracks” of research, each with a unique potential to advance the field. The first category “Track 1: Fundamental Mechanism Awards”, will target rigorous investigations using human stem/reprogrammed cells to elucidate fundamental molecular and cellular mechanisms pertinent to stem cell biology and/or regenerative medicine. Studies using in vitro human stem/reprogrammed cell models to elucidate disease mechanisms will also be supported through this track. The second category, “Track 2: Exploratory Concepts Awards” will target projects testing highly novel hypotheses that if proven, have the potential to dramatically and rapidly advance the field. Studies supported through both tracks of the Basic Biology Awards V will form the foundation for future translational and clinical advances, enabling the realization of the full potential of human stem cells and reprogrammed cells for therapies and as tools for biomedical innovation.
RFA 13-01: CIRM Disease Team Therapy Development III Awards
(Amended 2/11/13 )
The purpose of the Disease Team Therapy Development III Awards is to advance early clinical development of novel therapies derived from or targeting stem cells, potentially offering unique benefit with well-considered risk to persons with disease or serious injury. Disease Team Therapy Development III Awards will support actively managed teams to conduct milestone-driven preclinical and clinical development. The objective of this third call under the Disease Team initiative is to complete, in 4 years or less, a clinical trial under an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The objective for eligible CIRM Early Translational awardees under this RFA is to file a well-supported IND with the FDA within 4 years.
PA 12-08: CIRM Patent Assistance Fund Awards
The goal of the Patent Assistance Fund is to ensure adequate prosecution of intellectual property (“IP”) relating to CIRM Funded Inventions (“CFIs”) that have commercial relevance. CIRM’s program is intended to provide funding assistance to help ensure that non-profit Grantees preserve IP positions that are intended to enhance the marketability of CFIs and make downstream investment and development more likely.
RFA 12-06: CIRM Stem Cell Genomics Centers of Excellence Awards
The CIRM Stem Cell Genomics Centers of Excellence Awards will support the establishment and operation in California of one or two centers of excellence dedicated to the application of cutting-edge genomics approaches to substantive problems of human stem cell biology. These centers will provide expertise and resources for the development and application of new and innovative genomics approaches for stem cell biology and regenerative medicine. Combining genomic and bioinformatics approaches with stem cell research will accelerate fundamental understanding of human biology and disease mechanisms, enhance cell and tissue production and advance personalized cellular therapeutics.
RFA 09-04: CIRM Research Leadership Awards
The purpose of the CIRM Research Leadership Awards is to support robust and innovative stem cell research programs of the most promising researchers newly recruited to California. These awards will enable universities and research institutions to attract the very best stem cell scientists, with a focus on those who are early-to-mid career but have already established themselves as independent investigators and emerging national or international leaders in the stem cell field. They also will permit the recipients to pursue high-risk, high payoff, innovative studies that could not be adequately supported by other sources. The awardees will bolster California’s efforts in stem cell research and further CIRM’s mission to advance novel treatments and cures into medical practice.
PA 08-06: CIRM Conference Grants
This Program Announcement (PA) will support the development and conduct of scientific conferences relevant to stem cell research. A scientific conference is defined as an organized event where persons physically assemble to exchange scientific information or explore a defined scientific subject. Support of such conferences is contingent on the fiscal and programmatic priorities of CIRM. Conference grant awards are open to non-profit organizations in California.
Past requests for applications
RFA 12-07: CIRM Early Translational IV Research Awards
RFA 12-09: CIRM Strategic Partnership II Awards
RFA 12-05: CIRM Strategic Partnership I Awards
RFA 12-04: CIRM hPSC Repository Award
RFA 12-03: CIRM hiPSC Derivation Award
RFA 12-02: CIRM Tissue Collection for Disease Modeling Awards
RFA 12-01: CIRM New Faculty Physician Scientist Translational Research Awards
RFA 11-04: CIRM Creativity Awards
RFA 11-03: CIRM Basic Biology Awards IV
RFA 11-02: CIRM Early Translational III Research Awards
RFA 10-05: CIRM Disease Team Therapy Development Awards
RFA 10-05: CIRM Disease Team Therapy Development Awards - Part I Planning Award
RFA 10-04: CIRM Basic Biology Awards III
RFA 10-03: CIRM Targeted Clinical Development Awards
RFA 10-02: CIRM Tools and Technologies Awards II
RFA 10-01: CIRM Early Translational II Research Awards
RFA 09-04: CIRM Research Leadership Awards
- Cycle 1: Summaries of Review Reports
- Cycle 2: Summaries of Review Reports
- Cycle 8: Summaries of Review Reports
- Cycle 10: Summaries of Review Reports
- Cycle12: Summaries of Review Reports
RFA 09-03: CIRM Stem Cell Transplantation Immunology Awards
RFA 09-02: CIRM Basic Biology Awards II
RFA 09-01: CIRM Disease Team Research Awards
RFA 08-07: CIRM Basic Biology Awards I
RFA 08-05 : CIRM Early Translational Research Awards
RFA 08-04: CIRM Bridges to Stem Cell Research Awards
RFA 08-03: CIRM Research Training Program II
RFA 08-02: CIRM Tools and Technologies Awards
RFA 08-01: CIRM New Faculty Awards II
RFA 07-05: CIRM New Cell Lines Awards
RFA 07-04: CIRM Disease Team Planning Awards
RFA 07-03: CIRM Major Facilities Grant Program
RFA 07-02: CIRM New Faculty Awards
RFA 07-01: CIRM Shared Labs and Stem Cell Techniques Course Grant
RFA 06-02: CIRM Comprehensive Research Grant
RFA 06-01: CIRM SEED Grant
RFA 05-01: CIRM Training Grant
- Summaries of Review Reports (Type I)
- Summaries of Review Reports (Type II)
- Summaries of Review Reports (Type III)